ArticleBriefings in bioinformatics2026
CRESCENT: a deep learning framework with multi-scale attention for detecting recurrent copy number alterations.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Recurrent copy number alterations (CNAs) are fundamental drivers of tumorigenesis, yet identifying them reliably remains a challenge due to the extreme variability in their genomic scale and context. Current methods often struggle to balance sensitivity across focal, segmental, and arm-level events. Here, we present CRESCENT, a deep learning framework designed to detect recurrent CNAs by integrating multi-scale sampling with convolutional neural networks and self-attention mechanisms. By processing copy number profiles from 7689 cases across 20 The Cancer Genome Atlas (TCGA) cancer projects, CRESCENT learns to distinguish recurrent drivers from background noise through parallel feature fusion. In rigorous leave-one-project-out cross-validation, the model demonstrated robust generalization, achieving area under the curves of 0.894-0.967 for amplifications and 0.804-0.929 for deletions in representative cohorts (Bladder Urothelial Carcinoma, Sarcoma, Glioblastoma Multiforme, Uterine Corpus Endometrial Carcinoma). Finally, extending beyond the TCGA-specific cross-validation, we trained a unified pan-cancer model to assess CRESCENT's generalizability on simulated datasets and independent, non-TCGA cancer cohorts (CGCI and TARGET). Benchmarking against standard tools, including GISTIC2 and RUBIC, reveals that CRESCENT offers superior detection balance, identifying the highest total number of significant events across focal and broad scales. Moreover, extensive focal gene expression validation and pathway annotation, coupled with survival analysis, highlight that CRESCENT identifies critical oncogenic drivers and prognostic markers that conventional statistical methods often overlook. In all, CRESCENT provides a highly sensitive, generalized approach for decoding tumor evolution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.